Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Bhas 42 cells are an immortalized mouse fibroblast cell line established by transfecting BALB/c 3T3 cells with the v-Ha-ras oncogene [6, 11]. This genetic modification renders the cells "initiated" in the multistage process of carcinogenesis, making them highly sensitive to tumor promoters as well as initiating agents [1, 11]. They are the central component of the Bhas 42 cell transformation assay (CTA), an OECD-validated in vitro test used to identify chemical carcinogens and assess their potential to induce malignant transformation [1, 3, 11]. In these assays, the primary endpoint is the formation of morphologically distinct transformed foci, which represent cells that have lost contact inhibition and acquired invasive properties [1, 2]. While the cell line is a critical tool in regulatory toxicology and preclinical safety assessment, it is not a drug target itself; rather, it serves as a sensitive biological system for modeling the hallmarks of cancer development and screening for environmental or pharmaceutical hazards [2, 5, 10].
Not applicable (this is a cell line used for testing, not a therapeutic target)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Bhas 42 cell line (Bhas 42).